Endocrine Abstracts

Introduction: In patients with non-controlled type 2 diabetes mellitus (DM2) and obesity treated with oral therapy, liraglutide treatment should improve glycemic and metabolic control.

Materials and methods: Retrospective descriptive study. Liraglutide treatment was started in 46 outpatients with uncontrolled DM2. The effect of therapy was evaluated between September 2013 and January 2016. Age, sex, duration of diabetes, weight, BMI, HbA1c, fasting and postprandial glucose, lipid profile, were extracted at baseline/starting liraglutide, after 1, 3 and 6 months and at the end of follow up.

Results: Average age in 32 females was 59.3±18.2 years (range 35–82), in 14 males 55.8±16.3 (range 37–74 years); Duration of DM2 was 2 months–17 years in females, and 6 months–12 years in male patients. Baseline values:

Women: Weight 85–130 kg, BMI 35.2–48.9 kg/m², HbA1c 6.5–10.4%, fasting glucose 5.7–11.2 mmol/l, postprandial glucose 7.2–14.2 mmol/l, cholesterol 2.9–6.6 mmol/l, trygliceride 1.1–3.4 mmol/l, HDL 1–1.5 mmol/l, LDL 1.2–4.6 mmol/l.

Men: Weight 90–142 kg, BMI 35.2–41.7 kg/m², HbA1c 7.1–14.2%, fasting glucose 6.4–14.3 mmol/l, postprandial glucose 9.8–20.7 mmol/l, cholesterol 3.8–11.3 mmol/l, trygliceride 1.8–22.5 mmol/l, HDL 0.9–1.9 mmol/l, LDL 1.9–9.8 mmol/l.

After 1 month females lost 1–8 kg, males 0–3 kg. After 3 months women lost 1–16 kg, and men 1–4 kg. After 6 months females lost 3–18 kg (1 patient +2 kg), and males 2–4 kg (1 patient +4 kg).

At the end of follow up (21 months for women, and 15 months for men) female patients lost 2–18 kg, males 2–5 kg, although two female and two male had weight gain. At 15 female and six male patients final dose of liraglutide was 1.8 mg s.c., and in five women and two men basal insulin was added. HbA1c was 5.5–7.5% in female, and 5.9–9.1% in male patients.

Conclusion: Liraglutide therapy resulted in glycemic improvement and weight loss in most patients.